

FIRST LIGHT 03 March 2020

RESEARCH

BOB Economics Research | Weekly Wrap

Markets jittery as virus spreads

Balrampur Chini | NOT RATED

Higher ethanol sales to support profitability

Automobiles

Feb'20 Auto Sales - Weak for most segments; PVs, tractors ahead

SUMMARY

India Economics: Weekly Wrap

Global markets fell as COVID-19 outbreak spread beyond China to Italy, South Korea and Middle East. China's manufacturing and services PMI fell to an all-time low raising fresh concerns over global growth outlook. While bond yields fell, equity markets worldwide saw a sharp sell-off. US10Y yield fell by 32bps to an all-time low of 1.15% as investors expect Fed to intervene to support growth. JPY strengthened. Indian equity markets and INR fell due to FII outflows (US\$ 2.4bn). Indian 10Y yield fell 5bps as oil prices eased.

Click here for the full report.

Balrampur Chini

We recently met the management of Balrampur Chini Mills (BRCM). Key takeaways: (1) BRCM expects to crush ~5% lower sugarcane (~100mn quintals) in SS19-20 and produce ~1.14bn kg of sugar. Output of the sweetener is likely to decline YoY due to diversion of cane to produce B-heavy molasses. (2) Management estimates sugar recovery at 11.4% for the season despite diversion of ~40% of cane for B-heavy molasses (~12% if no diversion). (3) The company expects its cost of sugar production to average at ~Rs 30/kg at the EBIT level. Current selling prices are at Rs 32-32.5/kg.

Click here for the full report.

TOP PICKS

LARGE-CAPIDEAS

Company	Rating	Target
Bajaj Finance	Buy	5,200
<u>Cipla</u>	Buy	570
Eicher Motors	Buy	25,000
Petronet LNG	Buy	400
Reliance Industries	Buy	1,860

MID-CAPIDEAS

Company	Rating	Target
Alkem Labs	Buy	2,870
Greenply Industries	Buy	205
<u>Laurus Labs</u>	Buy	510
Transport Corp	Buy	355
Ashok Leyland	Sell	64

Source: BOBCAPS Research

DAILY MACRO INDICATORS

Indicator	Current	2D (%)	1M (%)	12M (%)
US 10Y yield (%)	1.15	(11bps)	(51bps)	(160bps)
India 10Y yield (%)	6.37	(1bps)	(21bps)	(101bps)
USD/INR	72.18	(0.9)	(1.2)	(1.8)
Brent Crude (US\$/bbl)	50.52	(3.2)	(15.1)	(22.4)
Dow	25,409	(1.4)	(11.5)	(2.4)
Shanghai	2,880	(3.7)	(3.2)	(3.8)
Sensex	38,297	(3.6)	(6.5)	6.2
India FII (US\$ mn)	27 Feb	MTD	CYTD	FYTD
FII-D	(270.9)	315.6	(1,253.3)	1,690.8
FII-E	(428.0)	877.1	2,249.7	9,638.9

Source: Bank of Baroda Economics Research

BOBCAPS Research

research@bobcaps.in



FIRST LIGHT



Automobiles

Feb'20 volume growth remained negative for most key segments, barring tractors. In addition to wholesale volume pressures from soft demand and destocking ahead of BS-VI, a few players witnessed production constraints due to supply disruptions in China-sourced components. PV growth stayed negative but MSIL's performance was resilient. Stress on 2W and MHCV wholesale volumes continued led by BS-IV inventory correction efforts. We continue to prefer PVs over 2Ws and CVs; MSIL and EIM are top picks and AL is a SELL.

Click here for the full report.

EQUITY RESEARCH 03 March 2020



WEEKLY WRAP

02 March 2020

Markets jittery as virus spreads

Global markets fell as COVID-19 outbreak spread beyond China to Italy, South Korea and Middle East. China's manufacturing and services PMI fell to an all-time low raising fresh concerns over global growth outlook. While bond yields fell, equity markets worldwide saw a sharp sell-off. US10Y yield fell by 32bps to an all-time low of 1.15% as investors expect Fed to intervene to support growth. JPY strengthened. Indian equity markets and INR fell due to FII outflows (US\$ 2.4bn). Indian 10Y yield fell 5bps as oil prices eased.

Sameer Narang | Aditi Gupta chief.economist@bankofbaroda.com

Markets

- Bonds: Global yields closed lower as concerns linger over spread of COVID-19. China's manufacturing and services PMI also fell sharply raising further concerns over global growth outlook. US 10Y yield fell by 32bps to hit a record low of 1.15% as markets are pricing a rate cut by Fed in Mar'20. Oil prices fell by (-) 3.2% (US\$ 51/bbl) over muted demand outlook. India's 10Y yield fell by 5bps (6.37%). System liquidity surplus was at Rs 3tn as on 28 Feb 2020 vs Rs 2.3tn in the previous week.
- Currency: Global currencies closed mixed this week. DXY weakened by (-) 1.1% in the week as Fed Chair hinted at rate cuts to combat the impact of COVID-19. JPY however, rose sharply by 3.3% on safe-haven demand. EUR also gained 1.7%. INR depreciated by (-) 0.7% on the back of FII outflows (US\$ 2.4bn) even as oil prices fell sharply.
- Equity: Barring Nikkei Global indices nosedived in the week, led by Dow, Dax (-12.4%) and FTSE (-11.1%). Renewed fears around spread of COIVID-19 outside of China dragged global markets down. There is widespread risk to global growth from spread of coronavirus. Following global cues, Sensex also fell by (-) 7%, with metal, auto and oil & gas stocks falling the most.
- Upcoming key events: In the current week, markets will closely follow news flow on spread of COVID-19 as well as manufacturing and services PMI of major economies-US, Eurozone, Japan and China. Apart from this, US jobs data is also scheduled to be released. Domestic markets will move inline with global markets.





NOT RATED

BALRAMPUR CHINI

Agriculture

02 March 2020

Higher ethanol sales to support profitability

We recently met the management of Balrampur Chini Mills (BRCM). Below are the key takeaways:

- Sugar production in India is expected to decline to ~26.5mn tonnes for sugar season 2019-20 (from ~33.2mt in SS18-19) mainly due to lower output in Maharashtra and Karnataka.
- Exports from India are projected at ~5mt this season aided by higher international sugar prices and government subsidy of ~Rs 10.44/kg.

Sugar

- BRCM expects to crush ~5% lower sugarcane (~100mn quintals) in SS19-20 and produce ~1.14bn kg of sugar. Output of the sweetener is likely to decline YoY due to diversion of cane to produce B-heavy molasses.
- Management estimates sugar recovery at 11.4% for the season despite diversion of \sim 40% of cane for B-heavy molasses (\sim 12% if no diversion).
- BRCM will fulfill its export entitlement by Q4FY20 and has got an additional export quota allotment of 85,000t in Feb'20. The company had sold the earlier export quota of 229,000 quintals at ~Rs 30/kg (incl. subsidies) and has also contracted the recently allocated quota at ~Rs 34/kg (incl. subsidies).
- Management expects its cost of sugar production to average at ~Rs 30/kg at the EBIT level. Current selling prices are at Rs 32-32.5/kg.

Ethanol

- BRCM plans to sell 120-125mn litres of ethanol in FY20 and ~150mn litres in FY21 (vs. ~111mn litres in FY19). About 60% of sales are planned via the B-heavy molasses route.
- The Gularia plant commenced production from Jan'20 and full benefits of this capacity should be seen in FY21, which should aid higher profitability.

Cogeneration

Management expects to sell 570mn units of power in FY20/FY21 (664mn units in FY19) at an average price of ~Rs 3.1/unit (-38% YoY). Realisation will decline due to change in pricing by the government from Apr'19. Volumes will be lower owing to higher internal consumption of bagasse at enhanced distillery capacities and sale of more bagasse outside post the reduction in power tariff (case on tariff cut pending in Allahabad High Court).

Arun Baid

research@bobcaps.in

Ticker/Price	BRCM IN/Rs 143
Market cap	US\$ 435mn
Shares o/s	228mn
3M ADV	US\$ 2.5mn
52wk high/low	Rs 195/Rs 110
Promoter/FPI/DII	41%/25%/34%

Source: NSE

STOCK PERFORMANCE



Source: NSE





AUTOMOBILES

02 March 2020

Feb'20 Auto Sales – Weak for most segments; PVs, tractors ahead

Feb'20 volume growth remained negative for most key segments, barring tractors. In addition to wholesale volume pressures from soft demand and destocking ahead of BS-VI, a few players witnessed production constraints due to supply disruptions in China-sourced components. PV growth stayed negative but MSIL's performance was resilient. Stress on 2W and MHCV wholesale volumes continued led by BS-IV inventory correction efforts. We continue to prefer PVs over 2Ws and CVs; MSIL and EIM are top picks and AL is a SELL.

Navin Matta | Nishant Chowhan, CFA research@bobcaps.in

MSIL resilient in PV segment: Domestic PV sales declined by an estimated 5-7% YoY in Feb'2O. Maruti Suzuki's (MSIL) domestic PV sales dipped 2% YoY (vs. double-digit declines for several peers), while exports rose 7%. Its compact segment volumes (-4% YoY) were likely hit by the discontinuation of diesel wholesale volumes. UV sales (+4% YoY) saw a healthy 37% MoM rise led by 'Vitara Brezza' (petrol) stocking. M&M's (MM) PV sales dropped 58% YoY with management citing challenges in parts supply from China due to Covid-19. Tata Motors' (TTMT) PV volumes fell 31% YoY. Among other major PV OEMs, domestic sales for Hyundai/Toyota/Honda slid 7%/12%/47% YoY.

Domestic 2W sales remain tepid: Domestic 2W sales continue to flounder due to (1) weak underlying demand, (2) ongoing BS-IV destocking effect, and (3) production constraints for BS-VI vehicles given supply disruptions from China. Domestic 2W volumes for Bajaj Auto (BJUAT) and TVS Motor (TVSL) declined 21% and 27% YoY respectively, partly offset by healthy export volume growth. Royal Enfield (RE) volumes rose 1% YoY led by a good response to its BS-VI motorcycles.

CV volumes still under pressure: MHCV volumes continue to falter with a lack of notable pre-buying. TTMT's domestic CV sales dropped 35% YoY as MHCV sales plunged 46% due to the weak macro climate. Ashok Leyland's (AL) domestic sales also fell 39% YoY led by a 47% fall in MHCVs. VECV volumes dropped 29% YoY.

Tractor sales strong: MM's tractors sales rose 19% YoY with domestic volume growth of 21% while sales for Escorts (ESC) also grew 19%. YTD tractor sales for MM/ESC are down 7%/5% YoY. Healthy monsoons and the rabi sowing trend should support volume growth in FY21.

RECOMMENDATION SNAPSHOT

Ticker	Price	Target	Rating
ALIN	75	64	SELL
BJAUT IN	2,792	3,560	ADD
EIM IN	17,013	25,000	BUY
HMCLIN	1,975	2,360	REDUCE
MM IN	462	600	ADD
MSIL IN	6,300	8,825	BUY
TTMT IN	125	212	ADD
TVSLIN	419	475	REDUCE

Price & Target in Rupees

SALES SNAPSHOT

Ticker	Volume	Y ₀ Y (%)	MoM (%)
AL IN	11,475	(37)	(3)
BJAUT IN	354,913	(10)	(10)
EIM IN*	68,122	(1)	(1)
MM IN	55,037	(27)	(27)
MSIL IN	147,110	(1)	(5)
TVSL IN	253,261	(15)	8
TTMT IN	40,516	(33)	(15)

Source: Company | *RE & VECV combined





Disclaimer

Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

ADD - Expected return from >+5% to +15%

REDUCE - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

Rating distribution

As of 29 February 2020, out of 85 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 50 have BUY ratings, 17 are rated ADD, 9 are rated REDUCE and 9 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

EQUITY RESEARCH 03 March 2020

FIRST LIGHT



We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

EQUITY RESEARCH 03 March 2020